The New York Times reports today that Gilead Sciences’ new medication, lenacapavir, which has shown high levels of effectiveness in preventing HIV infection when injected two times per year, will be made available in many poor countries around the world via generic versions, but not in Mexico.

Middle-income countries like Brazil, Colombia, Mexico, Russia and China will be forced to use Gilead’s own version of the drug, at higher prices, still to be determined.

Please read more here.